Insider Selling: AtriCure Inc. (NASDAQ:ATRC) SVP Sells 10000 Shares of Stock

Quantum Capital Management increased its stake in shares of AtriCure by 0.7% during the 1st quarter. Quantum Capital Management now owns …

AtriCure logoAtriCure Inc. (NASDAQ:ATRC) SVP Justin J. Noznesky sold 10,000 shares of the stock in a transaction on Monday, June 17th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the sale, the senior vice president now owns 94,068 shares of the company’s stock, valued at $2,822,040. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

NASDAQ ATRC traded down $0.76 during trading hours on Friday, hitting $31.38. The company’s stock had a trading volume of 151,864 shares, compared to its average volume of 220,718. AtriCure Inc. has a 52 week low of $26.11 and a 52 week high of $36.49. The stock has a market capitalization of $1.23 billion, a P/E ratio of -33.38 and a beta of 0.27. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.37 and a quick ratio of 3.69. The company’s 50-day moving average price is $30.11.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.04. The business had revenue of $53.97 million for the quarter, compared to analysts’ expectations of $52.45 million. AtriCure had a negative net margin of 7.98% and a negative return on equity of 14.35%. The firm’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.31) EPS. On average, research analysts anticipate that AtriCure Inc. will post -0.74 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. Macquarie Group Ltd. increased its stake in AtriCure by 1.0% in the 4th quarter. Macquarie Group Ltd. now owns 65,786 shares of the medical device company’s stock valued at $2,013,000 after buying an additional 681 shares during the last quarter. Quantum Capital Management increased its stake in shares of AtriCure by 0.7% during the 1st quarter. Quantum Capital Management now owns 127,035 shares of the medical device company’s stock worth $3,403,000 after purchasing an additional 845 shares during the last quarter. Bell Rock Capital LLC purchased a new stake in shares of AtriCure during the 1st quarter worth approximately $26,000. Rhumbline Advisers increased its stake in shares of AtriCure by 3.4% during the 1st quarter. Rhumbline Advisers now owns 48,738 shares of the medical device company’s stock worth $1,306,000 after purchasing an additional 1,594 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in shares of AtriCure by 31.0% during the 4th quarter. Legal & General Group Plc now owns 6,958 shares of the medical device company’s stock worth $213,000 after purchasing an additional 1,646 shares during the last quarter. Hedge funds and other institutional investors own 89.28% of the company’s stock.

A number of analysts have commented on ATRC shares. JPMorgan Chase & Co. set a €78.00 ($90.70) price target on shares of Porsche Automobil and gave the company a “neutral” rating in a research report on Friday, April 12th. BTIG Research started coverage on shares of GrubHub in a research report on Tuesday, April 2nd. They set a “buy” rating and a $95.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $120.00 price target (up previously from $115.00) on shares of Synopsys in a research report on Thursday, March 28th. BidaskClub raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 4th. Finally, Zacks Investment Research cut shares of Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, June 26th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $36.67.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.

Further Reading: What is the Beige Book?

Receive News & Ratings for AtriCure Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AtriCure and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Are There Any Catalysts to Propel Anaplan, Inc. (:PLAN) Forward?

Dedicated investors are constantly on the lookout for a bargain when it comes to stock picking. As of late, investors have been taking notice of Anaplan …

Dedicated investors are constantly on the lookout for a bargain when it comes to stock picking. As of late, investors have been taking notice of Anaplan, Inc. (:PLAN) shares. During recent trading, shares saw a move of 0.25% hitting a price of $57.24.

Investors are often trying to figure out the best way to analyze the stock market. When it comes to stock research, investors may use fundamental analysis, technical analysis, or a combination of both. Boiling down the two techniques, studying the fundamentals puts the focus on factors that may influence specific stocks, and studying the technicals puts the focus on market behavior analysis. Investors who study the fundamentals are typically trying to understand why stocks and markets move the way they do. Technical analysts are more concerned with spotting trends and trying to measure the characteristics of those trends. Some investors may prefer one method of stock research over another, but many investors may use a combination of both methods to help make sure that all the bases are covered.

Sometimes the stock market can be very confusing, even for the most seasoned investors. Even when expectations are met as predicted, the market may decide to move otherwise. This can cause uncertainty and second guessing. Keeping up with historical data as well as short-term and long-term trends may be very helpful. Over the past week, Anaplan, Inc. (:PLAN) shares have performed 8.89%. Pushing back over the last quarter, shares are 62.08%. Looking at stock performance for the past six months, shares are 105.40%. Since the start of the calendar year, shares have performed 115.15%.



Let’s take a quick look at some possible support and resistence levels for the stock. According to a recent spotcheck, company
Anaplan, Inc. (:PLAN) have been seen trading -0.11% away from the 50- day high. On the opposite end, shares have been trading 57.61% away from the 50-day low price. Taking a wider perspective, shares have been recently trading -0.11% off the 52-week high and 181.03% away from the 52-week low.

EPS

EPS is a portion of a company’s profit distributed to each outstanding common share. It acts as an indicator of a company’s profitability. EPS is considered to be the single most important variable in determining a the price of a share. Anaplan, Inc. (:PLAN)’s EPS growth this year is -166.00% and their trailing 12-month EPS is -1.12. As such, analysts can estimate Anaplan, Inc.’s growth for next year as 18.60%.

RETURNS AND RECOMMENDATION

While looking at past performance of a particular stock is important when speculating on its future, we must take other indicators into consideration as well. What are the returns? Anaplan, Inc. (:PLAN)’s Return on Assets (ROA) of -30.40% is an indicator of how profitable Anaplan, Inc. is relative to their total assets. ROA gives us an idea of how efficient management is at using assets to generate earnings We get ROA by dividing their annual earnings by their total assets. Anaplan, Inc.’s Return on Equity (ROE) is -55.20%, measure their profitability and reveals how much profit they generate with the money their shareholders. We calculate ROE by dividing their net income by their shareholder’s equity. Finally, Anaplan, Inc.’s Return on Investment, a measure used to evaluate the efficiency of an investment, calculated by the return of an investment divided by the cost, stands at -42.10%. Analysts on a consensus basis have a 2.20 recommendation on this stock.

Trying to extract profits from the stock market is not the easiest of tasks. In fact, it can be quite difficult. Amateur traders may be faced with tough challenges right out of the gate. Some traders may experience some crushing blows, and they have to figure out early on how to steady the ship. Completing all the necessary research can help the trader build a solid foundation, but when the rubber hits the road, it may take more than that just to stay afloat. Developing the proper mindset can be one of the biggest contributing factors for success in trading the stock market. This may take some time to achieve, but it may make all the difference when attempting to reach the goal of long lasting success.

Related Posts:

  • No Related Posts

Short Interest in AstroNova Inc (NASDAQ:ALOT) Expands By 23.3%

Boston Partners acquired a new stake in AstroNova during the 4th quarter worth approximately $1,023,000. Quantum Capital Management acquired a …

AstroNova logoAstroNova Inc (NASDAQ:ALOT) saw a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 21,700 shares, a growth of 23.3% from the April 30th total of 17,600 shares. Currently, 0.4% of the shares of the company are sold short. Based on an average daily volume of 37,900 shares, the short-interest ratio is currently 0.6 days.

ALOT has been the subject of a number of analyst reports. ValuEngine raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Zacks Investment Research raised shares of Grana y Montero SAA from a “sell” rating to a “hold” rating in a research note on Monday, June 10th.

Several hedge funds have recently modified their holdings of ALOT. Roubaix Capital LLC acquired a new stake in AstroNova during the 1st quarter worth approximately $2,242,000. Boston Partners acquired a new stake in AstroNova during the 4th quarter worth approximately $1,023,000. Quantum Capital Management acquired a new stake in AstroNova during the 4th quarter worth approximately $1,019,000. Punch & Associates Investment Management Inc. lifted its holdings in AstroNova by 7.5% during the 1st quarter. Punch & Associates Investment Management Inc. now owns 414,720 shares of the business services provider’s stock worth $8,456,000 after buying an additional 28,760 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in AstroNova by 8.7% during the 3rd quarter. Vanguard Group Inc. now owns 289,238 shares of the business services provider’s stock worth $6,248,000 after buying an additional 23,155 shares in the last quarter. Hedge funds and other institutional investors own 58.97% of the company’s stock.

Shares of AstroNova stock traded down $0.02 during mid-day trading on Friday, hitting $25.14. The stock had a trading volume of 37,400 shares, compared to its average volume of 35,986. The firm’s 50-day simple moving average is $25.84. AstroNova has a 12-month low of $16.74 and a 12-month high of $27.96. The company has a current ratio of 2.73, a quick ratio of 1.30 and a debt-to-equity ratio of 0.18. The company has a market cap of $180.74 million, a price-to-earnings ratio of 30.66, a P/E/G ratio of 2.39 and a beta of 0.25.

AstroNova (NASDAQ:ALOT) last issued its quarterly earnings data on Wednesday, June 5th. The business services provider reported $0.23 EPS for the quarter, topping the consensus estimate of $0.22 by $0.01. AstroNova had a net margin of 4.68% and a return on equity of 9.75%. The firm had revenue of $36.18 million for the quarter. On average, equities research analysts anticipate that AstroNova will post 0.9 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 24th. Stockholders of record on Monday, June 17th were issued a $0.07 dividend. The ex-dividend date was Friday, June 14th. This represents a $0.28 annualized dividend and a dividend yield of 1.11%. AstroNova’s dividend payout ratio is currently 34.15%.

AstroNova Company Profile

AstroNova, Inc designs, develops, manufactures, and distributes specialty printers, and data acquisition and analysis systems in the United States, Canada, Asia, Europe, Central and South America, and internationally. The company operates through two segments, Product Identification and Test & Measurement (T&M).

Featured Story: Should You Consider an Index Fund?

Receive News & Ratings for AstroNova Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AstroNova and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Quotient Ltd (NASDAQ:QTNT) Director Buys $27405.00 in Stock

Several hedge funds have recently added to or reduced their stakes in the business. Quantum Capital Management increased its position in shares of …

Quotient logoQuotient Ltd (NASDAQ:QTNT) Director Frederick Hallsworth acquired 3,150 shares of the company’s stock in a transaction dated Thursday, June 13th. The shares were bought at an average cost of $8.70 per share, with a total value of $27,405.00. Following the completion of the acquisition, the director now directly owns 74,398 shares in the company, valued at approximately $647,262.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Quotient stock traded up $0.43 during mid-day trading on Friday, hitting $10.49. The company’s stock had a trading volume of 376,184 shares, compared to its average volume of 362,449. The company has a current ratio of 4.59, a quick ratio of 3.98 and a debt-to-equity ratio of 72.27. The stock has a market cap of $669.73 million, a PE ratio of -5.46 and a beta of 0.88. The business has a 50 day moving average of $9.22. Quotient Ltd has a 12 month low of $5.52 and a 12 month high of $11.15.

Quotient (NASDAQ:QTNT) last posted its quarterly earnings results on Tuesday, May 28th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.03. The business had revenue of $8.28 million during the quarter, compared to the consensus estimate of $7.30 million. Equities analysts forecast that Quotient Ltd will post -1.59 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in the business. Quantum Capital Management increased its position in shares of Quotient by 0.7% in the first quarter. Quantum Capital Management now owns 388,302 shares of the company’s stock valued at $3,499,000 after acquiring an additional 2,744 shares during the period. Knott David M increased its position in shares of Quotient by 1.8% in the first quarter. Knott David M now owns 170,000 shares of the company’s stock valued at $1,532,000 after acquiring an additional 3,000 shares during the period. Lombard Odier Asset Management USA Corp increased its position in shares of Quotient by 4.0% in the first quarter. Lombard Odier Asset Management USA Corp now owns 260,000 shares of the company’s stock valued at $2,343,000 after acquiring an additional 10,000 shares during the period. Niemann Capital Management Inc. purchased a new position in shares of Quotient in the first quarter valued at about $101,000. Finally, Resources Investment Advisors Inc. purchased a new position in shares of Quotient in the first quarter valued at about $105,000. Hedge funds and other institutional investors own 63.91% of the company’s stock.

QTNT has been the subject of several recent research reports. ValuEngine raised shares of XCel Brands from a “sell” rating to a “hold” rating in a research note on Tuesday. BidaskClub raised shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a research note on Friday. Finally, Zacks Investment Research downgraded shares of Haynes International from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th.

About Quotient

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.

Further Reading: QQQ ETF

Receive News & Ratings for Quotient Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Quotient and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

SuperCom Ltd. (NASDAQ:SPCB) Short Interest Down 5.1% in May

Quantum Capital Management raised its position in SuperCom by 74.4% in the fourth quarter. Quantum Capital Management now owns 72,812 …

SuperCom logoSuperCom Ltd. (NASDAQ:SPCB) saw a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 320,500 shares, a decrease of 5.1% from the April 15th total of 337,900 shares. Based on an average daily volume of 38,200 shares, the days-to-cover ratio is currently 8.4 days. Approximately 2.9% of the company’s stock are sold short.

SPCB traded down $0.02 on Friday, hitting $1.06. 13,941 shares of the company traded hands, compared to its average volume of 16,314. The stock’s 50 day moving average is $1.13. The firm has a market cap of $16.45 million, a PE ratio of 12.22 and a beta of 0.82. SuperCom has a 12-month low of $0.98 and a 12-month high of $2.45.

SuperCom (NASDAQ:SPCB) last issued its earnings results on Monday, June 10th. The industrial products company reported $0.06 earnings per share for the quarter. The firm had revenue of $5.67 million during the quarter. Equities analysts forecast that SuperCom will post 0.15 earnings per share for the current fiscal year.

Several equities research analysts have weighed in on the company. Zacks Investment Research upgraded DLH from a “sell” rating to a “hold” rating in a report on Tuesday. HC Wainwright set a $4.00 price objective on Uranium Energy and gave the stock a “buy” rating in a research report on Tuesday, June 11th. Finally, ValuEngine cut Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st.

A number of institutional investors have recently modified their holdings of SPCB. Ibex Investors LLC purchased a new position in SuperCom in the fourth quarter valued at about $2,745,000. Quantum Capital Management raised its position in SuperCom by 74.4% in the fourth quarter. Quantum Capital Management now owns 72,812 shares of the industrial products company’s stock valued at $100,000 after purchasing an additional 31,053 shares during the period. Lehman & Derafelo Financial Resources LLC purchased a new position in SuperCom in the fourth quarter valued at about $87,000. Finally, Ridgewood Investments LLC raised its position in SuperCom by 54.4% in the first quarter. Ridgewood Investments LLC now owns 20,020 shares of the industrial products company’s stock valued at $28,000 after purchasing an additional 7,050 shares during the period. Hedge funds and other institutional investors own 18.26% of the company’s stock.

SuperCom Company Profile

SuperCom Ltd. provides digital identity, Internet of Things and connectivity, and cyber security products and solutions to governments, and private and public organizations worldwide. The company offers MAGNA, a common platform for ID registries, e-passports, biometric visas, automated fingerprint identification systems, digitized driver’s licenses, and electronic voter registration and election management.

See Also: Trading Ex-Dividend

Receive News & Ratings for SuperCom Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for SuperCom and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts